BioSpace News Archive

RaySearch Laboratories AB announces that University Medical Center Groningen in the Netherlands has placed an order for Micro-RayStation, RaySearch’s research software platform for radiation treatment planning and plan evaluation in small animal irradiation research.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 116,550 restricted stock units of Atara’s common stock to five newly hired employee.

Electromed, Inc., a leader in innovative airway clearance technologies, announced that it granted equity awards on July 1, 2023 as a material inducement to employment of James L. Cunniff, the newly appointed President and Chief Executive Officer of Electromed.

Syndax Pharmaceuticals, Inc. announced that on July 1, 2023 the Company granted inducement awards to purchase up to 31,400 shares of common stock to two new employees under the Company’s 2023 Inducement Plan.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Nymox Pharmaceutical Corporation is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors and the Company’s management.

BeiGene today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023.

Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts.

AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2023 financial results and third quarter 2023 outlook on Thursday, August 3, 2023, at 5:00 p.m. Eastern Time.

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses.